Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 2.4% in November: Crecon Report
January 18, 2013
- OrphanPacific’s Orphan Drug Biz Faces Rough Going with Rising Costs
January 17, 2013
- AZ K.K. President Hudson to Leave, Operations in Japan under Control of UK CFO
January 17, 2013
- Domestic Drug Makers Working to Escape Dependence on Long-Listed Drugs through New Product Development
January 17, 2013
- Tivantinib Fails to Meet Primary Endpoint in PII Trial for Colorectal Cancer: Daiichi Sankyo
January 17, 2013
- Epadel Fails to Meet Endpoint in PII Trial with NASH Patients
January 16, 2013
- Eisai's Farletuzumab Fails to Meet Primary Endpoint in PIII Trial
January 16, 2013
- Otsuka Files for Approval for New Dry Powder Inhaler of Meptin
January 16, 2013
- GMP Violations at Drug Substance Makers Prompt Series of New Voluntary Recalls of Generics; Stable Supplies Disrupted
January 16, 2013
- Astellas and Sanwa Kagaku Launch Hyperkalemia Treatment Argamate Granule
January 15, 2013
- Different Reactions from Industry Following Announcement of Stricter Requirements on Sales of Epadel OTC
January 15, 2013
- Takeda Launches Hyperlipidemia Treatment Lotriga
January 11, 2013
- Eisai Ties Up with Epizyme, RMS to Develop a Companion Diagnostic
January 11, 2013
- Seiichiro Matsumura Serves as New President of Alcon Japan
January 11, 2013
- Nichi-Iko Voluntarily Recalls Picillibacta IV Inj. 1.5 g
January 11, 2013
- Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
- Janssen Resumes Supply of Doxil
January 10, 2013
- Daiichi Sankyo to Jointly Develop Autoimmune Disease Therapy with Amplimmune
January 10, 2013
- Top Officials of Major Drug Makers Express Concerns Mixed with Some Understanding About New Pricing Rule for Long-Listed Drugs
January 10, 2013
- BI, Eli Lilly Plan to Submit SGLT-2 Inhibitor Empagliflozin for Approval in Japan, US, and Europe in 2013
January 10, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…